Quantum Biopharma Ltd. (QNTM) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Quantum Biopharma Ltd. Do?
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada. Quantum Biopharma Ltd. (QNTM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Zeeshan Saeed. With a market capitalization of $26M, QNTM is one of the notable companies in the Healthcare sector.
Quantum Biopharma Ltd. (QNTM) Stock Rating — Reduce (April 2026)
As of April 2026, Quantum Biopharma Ltd. receives a Reduce rating with a composite score of 24.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.QNTM ranks #3,906 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Quantum Biopharma Ltd. ranks #668 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
QNTM Stock Price and 52-Week Range
Quantum Biopharma Ltd. (QNTM) currently trades at $3.50. The stock gained $0.23 (7.0%) in the most recent trading session. The 52-week high for QNTM is $38.25, which means the stock is currently trading -90.8% from its annual peak. The 52-week low is $2.07, putting the stock 69.1% above its annual trough. Recent trading volume was 111K shares, suggesting relatively thin trading activity.
Is QNTM Overvalued or Undervalued? — Valuation Analysis
Quantum Biopharma Ltd. (QNTM) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.
At current multiples, Quantum Biopharma Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Quantum Biopharma Ltd. Profitability — ROE, Margins, and Quality Score
Quantum Biopharma Ltd. (QNTM) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -348.5% versus the sector average of -33.1%.
On a margin basis, Quantum Biopharma Ltd. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -404518.9% (sector: -66.1%). Net profit margin stands at -373916.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
QNTM Debt, Balance Sheet, and Financial Health
Balance sheet data for QNTM is evaluated through our stability factor. Total debt on the balance sheet is $824,922. Cash and equivalents stand at $6M.
QNTM has a beta of 1.23, meaning it is more volatile than the broader market — a $10,000 investment in QNTM would be expected to move 22.8% more than the S&P 500 on any given day. The stability factor score for Quantum Biopharma Ltd. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Quantum Biopharma Ltd. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Quantum Biopharma Ltd. reported revenue of $0 and earnings per share (EPS) of $-13.12. Net income for the quarter was $-15M. Gross margin was 100.0%. Operating income came in at $-16M.
In FY 2024, Quantum Biopharma Ltd. reported revenue of $0 and earnings per share (EPS) of $-13.12. Net income for the quarter was $-15M. Operating income came in at $-16M.
In FY 2023, Quantum Biopharma Ltd. reported revenue of $-4M and earnings per share (EPS) of $-0.46. Net income for the quarter was $-18M. Revenue grew -150.5% year-over-year compared to FY 2022. Operating income came in at $-24M.
In FY 2022, Quantum Biopharma Ltd. reported revenue of $-2M. Net income for the quarter was $-24M. Revenue grew 79.4% year-over-year compared to FY 2021. Operating income came in at $-27M.
Over the past 8 quarters, Quantum Biopharma Ltd. has demonstrated a growth trajectory, with revenue expanding from $-5M to $0. Investors analyzing QNTM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
QNTM Dividend Yield and Income Analysis
Quantum Biopharma Ltd. (QNTM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
QNTM Momentum and Technical Analysis Profile
Quantum Biopharma Ltd. (QNTM) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 46/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.
QNTM vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Quantum Biopharma Ltd. (QNTM) ranks #668 out of 838 stocks based on the Blank Capital composite score. This places QNTM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing QNTM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full QNTM vs S&P 500 (SPY) comparison to assess how Quantum Biopharma Ltd. stacks up against the broader market across all factor dimensions.
QNTM Next Earnings Date
No upcoming earnings date has been announced for Quantum Biopharma Ltd. (QNTM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy QNTM? — Investment Thesis Summary
The quantitative profile for Quantum Biopharma Ltd. suggests caution. The quality score of 32/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance. High volatility (stability score 14/100) increases portfolio risk.
In summary, Quantum Biopharma Ltd. (QNTM) earns a Reduce rating with a composite score of 24.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on QNTM stock.
Related Resources for QNTM Investors
Explore more research and tools: QNTM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare QNTM head-to-head with peers: QNTM vs AZN, QNTM vs SLGL, QNTM vs VMD.